Publication Name	World Journal of Hematology
Manuscript ID	14769
Country	Australia

Received	2014-10-23 09:03
Peer-Review Started	2014-10-24 17:16
To Make the First Decision	2014-10-28 14:17
Return for Revision	2014-11-03 14:47
Revised	2014-11-11 14:04
Second Decision	2014-12-11 08:54
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2014-12-17 16:54
Articles in Press	2014-12-17 16:54
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-01-28 16:21
Publish the Manuscript Online	2015-02-04 11:55

ISSN	2218-6204 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Hematology
Manuscript Type	Minireviews
Article Title	Role of novel oral anticoagulants in the management and prevention of venous thromboembolism
Manuscript Source	Invited Manuscript
All Author List	Helen E Jo and David J Barnes
Funding Agency and Grant Number
Corresponding Author	Dr. Helen E Jo, Department of Respiratory Medicine, Royal Prince Alfred Hospital, Missenden Rd, Camperdown NSW 2050, Sydney, Australia. helenjo3008@gmail.com
Key Words	Venous thromboembolism; Pulmonary embolism; Novel oral anticoagulants; Factor Xa inhibitors; Direct thrombin inhibitors
Core Tip	Novel oral anticoagulants (NOACs) are emerging as viable alternatives to VKA in the treatment of venous thromboembolism. Trials have shown that they are as efficacious as current standard treatment with LMWH followed by VKA, and have potentially less bleeding associated with them. The regimes are simple and no monitoring is required and therefore it has the potential to reduce the burden of anticoagulation. Caution is required however, as testing of anticoagulant effect is limited and patient selection is important as many of the NOACs are metabolized in the liver and cleared by the kidney.
Publish Date	2015-02-04 11:55
Citation	Jo HE, Barnes DJ. Role of novel oral anticoagulants in the management and prevention of venous thromboembolism. World J Hematol 2015; 4(1): 1-9
URL	http://www.wjgnet.com/2218-6204/full/v4/i1/1.htm
DOI	http://dx.doi.org/10.5315/wjh.v4.i1.1

Full Article (PDF)	WJH-4-1.pdf
Full Article (Word)	WJH-4-1.doc
Manuscript File	14769-Review.docx
Answering Reviewers	14769-Answering reviewers.pdf
Conflict-of-Interest Disclosure Form	14769-Conflict-of-interest statement.pdf
Copyright License Agreement	14769-Copyright assignment.pdf
Peer-review Report	14769-Peer review(s).pdf
Scientific Misconduct Check	14769-CrossCheck.jpg
Scientific Editor Work List	14769-Scientific editor work list.pdf